

ARGENICA TO PRESENT ARG-007 DATA AT FETAL AND NEONATAL SCIENTIFIC CONFERENCE

Perth, Australia; 4 September 2023 - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other brain injury, is pleased to announce Dr Adam Edward, Argenica’s Neonatal Scientific and Regulatory Advisor and Post Doctoral Research Officer at the Perron Institute for Neurological and Translational Science, is presenting a talk today at the 49th annual Fetal and Neonatal Physiological Society (FNPS) meeting in Queenstown, New Zealand.

The talk is titled *ARG-007: a promising neuroprotective peptide for hypoxic ischaemic encephalopathy*. The slides are attached to this announcement.


Argenica’s Managing Director, **Dr Liz Dallimore said:** “We are delighted that Dr Edwards has been invited to present preclinical data on the efficacy of ARG-007 in models of hypoxic ischaemic encephalopathy. Dr Edwards will use the opportunity to inform the scientific community of this exciting and world leading research.”

This announcement has been approved for release by Argenica’s Managing Director.

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has recently completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica is now progressing towards a Phase 2 clinical trial in ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions, including in TBI, HIE and Alzheimer’s Disease.



ARG-007: a promising neuroprotective peptide for hypoxic ischaemic encephalopathy

Adam B. Edwards, Vincent W. Clark, Aline Domingos, Rachel Glossop, Neville W. Knuckey, Bruno P. Meloni



Sir Charles
Gairdner Hospital

40 perron
institute


Disclaimer

- Argenica Therapeutics Ltd is the commercial entity leading the clinical development of ARG-007 as a neurotherapeutic
- Appointments
 - Shareholder of Argenica Therapeutics Ltd
 - Neonatal Scientific and Regulatory Advisor of Argenica Therapeutics Ltd

Presentation overview

- The unmet need in HIE
- ARG-007 as a neurotherapeutic
- Modified Rice-Vannucci rat model of HIE
- ARG-007 efficacy PND7 and PND10 rats
- Future directions


The unmet need in HIE








LMIC – low middle income country

HELIX - a large, randomised controlled trial of therapeutic hypothermia for HIE in LMICs, found that treatment did not reduce the combined outcome of death or disability at 18 months of age and increased mortality







ARG-007 as a neurotherapeutic



ARG-007 as a neurotherapeutic





Modified Rice-Vannucci model




ARG-007 efficacy in the PND7 rat


ARG-007 efficacy as a standalone therapy




ARG-007 efficacy after hypothermia



ARG-007 efficacy in the PND7 rat



ASX Announcement 3 November 2021





Unpublished observation


ARG-007 efficacy in the PND10 rat

Neuropathological correlates:



- Neocortical infarct
- Striatal infarct
- Subcortical infarct
- Foci haemorrhage




48 hour ADC



4 week T2




4 week T2




4 week ADC

Future planned studies



ARG-007 neuroprotection in
preterm asphyxia \pm LPS
challenge



ARG-007 neuroprotection in
term asphyxia with recovery
and 25 day behavioural
assessments

Acknowledgements

■ Research

Prof Bruno Meloni

Prof Neville Knuckey

Prof Jane Pillow

A/Prof Kasper Kyng

Dr Tim Rosenow

Dr Kirk Feindell

Mr Vince Clark

Ms Aline Domingos

Miss Rachel Glossop

■ Funding

Argenica Therapeutics Ltd

Stan Perron Charitable Foundation

Telethon Perth Children's Hospital Research Fund

Channel 7 Telethon Trust

Charlies Foundation for Research

University of Western Australia

Perron Institute

Department of Neurosurgery, SCGH

Johanna Sewell Memorial Fund

